Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

119.65 -1.77 (-1.46%)
Streaming Delayed Price Updated: 2:11 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,764,769
Open 121.03
Bid (Size) 119.64 (300)
Ask (Size) 119.70 (400)
Prev. Close 121.42
Today's Range 119.06 - 121.30
52wk Range 73.31 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
From Daiichi Sankyo
Via Business Wire

Performance

YTD
+12.4%
+12.4%
1 Month
+3.5%
+3.5%
3 Month
+9.6%
+9.6%
6 Month
+39.6%
+39.6%
1 Year
+51.1%
+51.1%

More News

Read More
News headline image
1 Momentum Stock on Our Buy List and 2 We Question
Via StockStory
Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗
Via Chartmill
News headline image
Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
Via MarketMinute
Topics Bonds
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
Via Finterra
Topics Economy World Trade
News headline image
Why Terns Pharmaceuticals Stock Rocked the Market in March ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
Via MarketMinute
Topics Intellectual Property
News headline image
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
From Merck & Co., Inc.
Via Business Wire
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
From Merck & Co., Inc.
Via Business Wire
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
Via Finterra
Topics Initial Public Offering
News headline image
Merck Just Made a Big Bet on a New Cancer Growth Engine ↗
Via MarketBeat
News headline image
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
From Merck & Co., Inc.
Via Business Wire
News headline image
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
From Merck & Co., Inc.
Via Business Wire
News headline image
1 Reason Eli Lilly Stock Is Still a Buy ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗
Via The Motley Fool
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
Via MarketMinute
Topics Intellectual Property

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 119.65
When was Merck & Co last traded?
The last trade of Merck & Co was at 04/13/26 02:11 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 302.88B
How many shares of Merck & Co are outstanding?
Merck & Co has 303B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.